XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Cash flows from operating activities:              
Net loss $ (5,726,812) $ (10,367,061) $ (5,884,223) $ 11,264,842 $ (21,597,852) $ (4,282,828)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation expense         132,512 121,657  
Stock-based compensation expense         13,776,951 33,803,120  
Non-cash interest expense         171,771  
Merger transaction costs         7,099,353  
Change in fair value of convertible promissory notes     (48,468,678)  
Loss on Series A Preferred Stock issuance         799,990  
Loss on issuance of commitment shares     890,000  
Change in fair value of warrants (64,959)   (7,613)   (57,406) (14,428)  
Issuance of written call option          
Change in fair value of written call option derivative liabilities         7,064  
Amortization of right-of-use asset         290,899 178,377  
Change in operating assets and liabilities:              
Prepaid expenses and other assets         10,539 (365,134)  
Other assets         9,957 (68,446)  
Accounts payable         (1,992,314) 2,323,809  
Accrued expenses and other liabilities         (450,346) (960,172)  
Operating lease liabilities         (270,250) (186,499)  
Net cash used in operating activities         (10,147,310) (8,951,044)  
Cash flows from investing activities:              
Net cash used in investing activities          
Cash flows from financing activities:              
Cash acquired in connection with the reverse recapitalization         229,328  
Proceeds from issuance of Series A Preferred Stock         2,000,000  
Proceeds from issuance of Series C Preferred Stock         4,000,000  
Nonrefundable prepaid proceeds towards anticipated Series A-1 Preferred Stock issuance         3,000,000  
Capital contributions         3,500,000  
Payment of offering costs associated with the sales agreement         (100,000)  
Proceeds from issuance of shares under the sales agreement, net of offering costs         3,101,409  
Proceeds from loan agreement         3,400,000 1,000,000  
Net cash provided by financing activities         9,901,409 10,229,328  
Net (decrease) increase in cash         (245,901) 1,278,284  
Cash – beginning of period   $ 1,282,995   $ 1,052,397 1,282,995 1,052,397 $ 1,052,397
Cash – end of period $ 1,037,094   $ 2,330,681   1,037,094 2,330,681 $ 1,282,995
Supplementary disclosure of noncash investing and financing activities:              
Conversion of convertible promissory notes into common stock in connection with Merger         46,622,627  
Issuance of shares in connection with the loan agreement         65,406  
Repurchase of Series B preferred stock         3,613,000  
Issuance of common stock for net liabilities upon reverse recapitalization, net of transaction costs         (3,113,309)  
Right-of-use assets obtained in exchange for operating lease liabilities         1,513,607  
Deferred offering costs in accounts payable and accrued expenses         104,000  
Deferred offering cost amortization         $ 13,077